Genomic and transcriptomic characterization of pre-operative chemotherapy response in patients with osteosarcoma

• Published in: Scientific reports 2023-11, Vol.13 (1), p.20914-20914, Article 20914
• Main Authors: Yang, Yongkun, Huang, Zhen, Yuan, Mingming, Rui, Jinqiu, Chen, Rongrong, Jin, Tao, Sun, Yang, Deng, Zhiping, Shan, Huachao, Niu, Xiaohui, Liu, Weifeng
• Format: Article
• Language: English
• Subjects: 692/308/53/2423; 692/308/575; 692/4028/67/1344; Bone cancer; Bone Neoplasms - drug therapy; Bone Neoplasms - genetics; Bone Neoplasms - surgery; Cardiomyopathy; Chemotherapy; Copy number; Gene Expression Profiling; Genomics; Homologous recombination; Homologous recombination repair; Humanities and Social Sciences; Humans; multidisciplinary; Osteosarcoma; Osteosarcoma - drug therapy; Osteosarcoma - genetics; Osteosarcoma - surgery; Sarcoma; Science; Science (multidisciplinary); Transcriptome; Transcriptomes; Transcriptomics
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-46857-8

Osteosarcoma is a heterogeneous disease with regard to its chemotherapy response and clinical outcomes. This study aims to investigate the genomic and transcriptomic characteristics related to pre-operative chemotherapy response. Samples from 25 osteosarcoma patients were collected to perform both whole exome and transcriptome sequencing. Osteosarcoma had significant amount of chromosomal copy number variants (CNVs). Chemotherapy responders showed the higher chromosomal CNV burden than non-responders (p = 0.0775), but the difference was not significant. The percentage of COSMIC signature 3, associated with homologous recombination repair deficiency, was higher in responders (56%) than in non-responders (45%). Transcriptomic analysis suggested that 11 genes were significantly up-regulated in responders and 18 genes were up-regulated in non-responders. Both GSEA and KEGG enrichment analysis indicted that four pathways related to cardiomyopathy were up-regulated in responders, while neuroactive ligand − receptor interaction was up-regulated in non-responders. Finally, a previously published chemoresistant model was validated using our dataset, with the area under the curve of 0.796 (95% CI, 0.583–1.000). Osteosarcoma had the heterogeneous mutational profile with frequent occurrence of CNVs. Transcriptomic analysis identified several signaling pathways associated with chemotherapy responsiveness to osteosarcoma. Transcriptomic signatures provides a potential research direction for predicting the chemotherapy response.